Ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) were both FDA-approved for R/R IDH-mutated AML based on the respective single-arm monotherapy studies [83,84,85]. The gene discussed is IDH2; the disease is acute myeloid leukemia.